• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implicat

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2021 Dec 28;S1201-9712(21)01255-8.
doi: 10.1016/j.ijid.2021.12.356. Online ahead of print.
Community seroprevalence and risk factors for SARS CoV-2 infection in different subpopulations in Vellore, India and its implications for future prevention


Divya Dayanand[SUP] 1 [/SUP], Indhuja Irudhayanathan[SUP] 1 [/SUP], Debasree Kundu[SUP] 1 [/SUP], Abi Manesh[SUP] 1 [/SUP], Vinod Abraham[SUP] 2 [/SUP], Kundavaram Pp Abhilash[SUP] 3 [/SUP], Binila Chacko[SUP] 4 [/SUP], Mahesh Moorthy[SUP] 5 [/SUP], Prasanna Samuel[SUP] 6 [/SUP], Pimnara Peerawaranun[SUP] 7 [/SUP], Mavuto Mukaka[SUP] 8 [/SUP], Jayaraj Joseph[SUP] 9 [/SUP], Mohanasankar Sivaprakasam[SUP] 9 [/SUP], George M Varghese[SUP] 10 [/SUP]



Affiliations

Abstract

Objectives: To inform public health policy decisions through assessment of IgG antibody seroprevalence in the population and the risk factors for SARS-CoV-2 infection.
Methods: We estimated the seroprevalence of IgG antibodies among different subpopulations at the end of the first and second waves of the pandemic. We also assessed various risk factors associated with the seropositivity including socio demography, IgG antibodies against endemic human coronavirus and vaccination status.
Results: Of the 2433 consented participants, the overall estimated seroprevalence at the end of first and second waves were 28.5% (95% CI:22.3%-33.7%) and 71.5% (95% CI:62.8%-80.5%), respectively. The accrual of IgG positivity was heterogeneous, with highest seroprevalence among the urban slum population(75.1%). Vaccine uptake was varied among the subpopulations, with low rates (<10%) among the rural and urban slums. The majority of seropositive individuals (75%) were asymptomatic. Residence in urban slums (OR 2.02; 95% CI:1.57-2.6; p<0.001), middle socioeconomic status (OR 1.77; 95% CI:1.17-2.67; p=0.007), presence of diabetes (OR 1.721; 95% CI:1.148-2.581; p=0.009), and hypertension (OR 1.75; 95% CI:1.16-2.64; p=0.008) were associated with seropositivity on multivariable analyses.
Conclusion: Although considerable population immunity has been reached with more than two-thirds seropositivity, improved vaccination strategies among unreached subpopulations and high-risk individuals are suggested for better preparedness in future.

Keywords: COVID; India; SARS CoV 2; Seroprevalence.
 
Back
Top Bottom